An Open Study of the Safety and Efficacy of Saizen, (Recombinant Human Growth Hormone, r-hGH), in Children Born With Serious Intra-uterine Growth Retardation (IUGR) Treated to Final Height

Trial Profile

An Open Study of the Safety and Efficacy of Saizen, (Recombinant Human Growth Hormone, r-hGH), in Children Born With Serious Intra-uterine Growth Retardation (IUGR) Treated to Final Height

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2015

At a glance

  • Drugs Somatropin (Primary)
  • Indications Fetal growth retardation
  • Focus Therapeutic Use
  • Sponsors Merck KGaA
  • Most Recent Events

    • 04 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top